HONG KONG – Celltrion Inc., of Incheon, South Korea, recently received marketing approval from the European Commission for its biosimilar trastuzumab, Herzuma. Based on Roche Holding AG and Genentech Inc.'s targeted therapy, Herceptin, Herzuma is cleared for marketing in the 28 member states of the European Union (EU), in addition to Norway, Liechtenstein and Iceland.